Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06917079 · ClinicalTrials.gov registry record · Phase 1
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
A Phase 1 study of Non-Small Cell Lung Cancer and NSCLC, sponsored by TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics).
- Recruiting
- Registry status
- Phase 1
- Development phase
- 387
- Enrollment target
- 11
- Study locations
NCT06917079: Recruiting Phase 1 study of Non-Small Cell Lung Cancer and NSCLC, sponsored by TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics).
NCT06917079 is a Phase 1 study of Non-Small Cell Lung Cancer and NSCLC that is actively recruiting participants, run by TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics). The registered enrollment target is 387 participants, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (41% lower). The trial reports 11 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06917079, a Phase 1 study of Non-Small Cell Lung Cancer and NSCLC, is actively recruiting participants, sponsored by TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics).
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 387 participants
- Enrollment target
- 11
- Study locations
Study Summary
A first in human study to evaluate the safety and preliminary antitumor activity of BBO-11818, a pan-KRAS inhibitor, in subjects with locally advanced unresectable or metastatic KRAS mutant solid tumors.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Pemetrexed
- DRUG Cetuximab
- DRUG BBO-11818
- DRUG Platinum chemotherapy (cisplatin or carboplatin)
Study Locations (11)
Texas
- Sarah Cannon Research Institute at Mary Crowley - Dallas
- The University of Texas MD Anderson Cancer Center - Houston
- NEXT Oncology - San Antonio
California
- The Angeles Clinic and Research Institute - West Los Angeles Office - Los Angeles
- University of California San Diego Moores Cancer Center - San Diego
New York
- NYU Langone Health - New York
- Columbia University Irving Medical Center - New York
Florida
- Moffitt Cancer Center - Tampa
Massachusetts
- Massachusetts General Hospital - Boston
Utah
- Huntsman Cancer Institute - Salt Lake City
Washington
- Fred Hutchinson Cancer Center - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 387 participants |
| Start Date | 2025-03-31 |
| Est. Completion | 2029-09 |
| Phase | Phase 1 |
What NCT06917079 shows while recruiting
NCT06917079 is an interventional study that assigns participants to a tested intervention. The registered 387 participants enrollment target is mid-sized for trials with a published cap, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (41% lower).
The record links to 10 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 5 interventions - of which Pembrolizumab is the first listed.
NCT06917079 lists 11 locations in 7 states (Texas, California, New York).
Frequently Asked Questions
What is clinical trial NCT06917079 about?
NCT06917079 is a clinical study titled "BBO-11818 in Adult Subjects With KRAS Mutant Cancer". A first in human study to evaluate the safety and preliminary antitumor activity of BBO-11818, a pan-KRAS inhibitor, in subjects with locally advanced unresectable or metastatic KRAS mutant solid tumors.
What is the current status of trial NCT06917079?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 387 participants. The study started on 2025-03-31. Estimated completion is 2029-09.
What conditions does trial NCT06917079 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, NSCLC, PDAC - Pancreatic Ductal Adenocarcinoma, CRC, Colorectal Cancer, Metastatic Colorectal Cancer (CRC).
What interventions are being tested in trial NCT06917079?
The interventions under investigation include: Pembrolizumab (DRUG), Pemetrexed (DRUG), Cetuximab (DRUG), BBO-11818 (DRUG), Platinum chemotherapy (cisplatin or carboplatin) (DRUG).
Who is sponsoring clinical trial NCT06917079?
This trial is sponsored by TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics), which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06917079 being conducted?
This trial has 11 study locations across California, Florida, Massachusetts, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06917079's enrollment target sits among peer trials
387 104th of 454 higher than 351 of 454 other Non-Small Cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03761108 · 387 participants · Phase 1
Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma
- NCT05572632 · 387 participants · NA
Rehabilitation in Safety-net Environments (RISE) to Improve Outcomes in Vulnerable Patients With COPD
- NCT04092010 · 388 participants · NA
Improving Preschool Outcomes by Addressing Maternal Depression in Head Start
- NCT05157880 · 388 participants · NA
Building Resiliency in Dyads of Patients With an ANI Admitted to the Neuro-ICU and Their Informal Caregivers
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI